• Advancing gastrointestinal health naturally

    Our Gastrointestinal Reprogramming Product (GaRP) product is a microbiome-targeted multi-component dietary supplement that has been designed to address the primary underlying factors associated with gastrointestinal disorders.

  • Exclusive Global License Agreement with Zoetis

    Anatara has signed an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach. More >>

Company description

Anatara Lifesciences is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Our lead product Detach is a natural product that has been shown to aid in the control of scour in piglets. Anatara has signed an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.

Video overview

Latest news All news

  • Investor Presentation and Strategy Update

    Anatara is pleased to release its latest presentation and strategy update that will be delivered to institutional investors this week. 

    Please click here to view the ASX announcement.

  • Letter to shareholders

    Anatara is pleased to release a copy of a letter from Chairman, Dr Jay Hetzel, to shareholders which accompanies the investor presentation released today.
     
    Please click here to view the ASX announcement.

Investors

Investors Home

Pause